GLP-1 patches: TikTok trend or legitimate delivery method?

What did @casharroyo actually say?

On day four of a month-long test, the creator tried a transdermal patch marketed as a "GLP-1 patch" and told viewers it works because "it's berberine" and is "supposed to mimic the GLP-1." She positioned this as an alternative for people who want to avoid injections or can't swallow supplements. She's not making a dramatic cure claim, she's framing herself as a guinea pig and promising a real review. That's actually a reasonable setup. The problem is the premise she's working from is shaky before she even finishes day four.

Credit where it's due: she didn't claim this was equivalent to semaglutide or Ozempic by name. She said it "mimics" GLP-1, which is technically what the marketing says, not necessarily what the evidence supports. Her transparency about being early in the process is fair. But 196,000 people watching someone test a product based on a mechanistic claim that doesn't hold up is worth unpacking.

Does the science back this up?

Berberine has real metabolic data behind it. The connection to GLP-1 is real but indirect, and calling a berberine patch a "GLP-1 patch" is a stretch that the evidence doesn't fully support.

Berberine does appear to influence GLP-1 secretion. A 2012 study by Zhao et al. in the journal Metabolism found that berberine stimulated GLP-1 release from intestinal L-cells in animal models. A 2015 human trial by Zhang et al. in Diabetes Care showed berberine improved glycemic control in type 2 diabetes patients, with mechanisms likely including AMPK activation and modest GLP-1 effects. So the biology isn't invented. But "influences GLP-1 secretion" is a long way from "mimics GLP-1 receptor agonists like semaglutide."

The bigger issue is the patch delivery system itself. Berberine has notoriously poor oral bioavailability, around 0.36% in some estimates (Tan et al., 2013, European Journal of Drug Metabolism and Pharmacokinetics). Transdermal delivery of berberine is even less studied. There is minimal peer-reviewed evidence that berberine absorbs meaningfully through intact skin at doses sufficient to produce metabolic effects. The patch format is not supported by robust clinical data.

What did they get wrong (or right)?

The creator got the general category right: berberine does interact with GLP-1 pathways. She got the framing wrong: calling these "GLP-1 patches" implies a mechanism and potency that the product almost certainly doesn't deliver.

What's misleading is the shorthand. "It's supposed to mimic the GLP-1" collapses a complex and contested pharmacological claim into a tidy talking point. Actual GLP-1 receptor agonists like semaglutide bind directly to GLP-1 receptors with high affinity. Berberine nudges GLP-1 secretion upstream. Those are fundamentally different mechanisms, and the clinical effect sizes are not comparable. A 2021 meta-analysis by Blond et al. in Pharmacological Research found berberine produced modest weight loss of roughly 2-3 kg in trials, compared to semaglutide trials showing 10-15% body weight reduction (Wilding et al., 2021, NEJM).

She also doesn't address whether a patch can even deliver berberine transdermally in meaningful amounts. That's not a small detail. It's the whole product premise.

What should you actually know?

Berberine is a legitimate compound with real metabolic research. It is not a GLP-1 receptor agonist, and a patch version has essentially no clinical trial support for efficacy or bioavailability.

If you have PCOS (which the hashtags suggest is the creator's context), berberine has some relevant data. A 2012 randomized trial by An et al. in Fertility and Sterility found berberine improved insulin resistance and hormonal markers in PCOS patients, performing comparably to metformin in that cohort. That's genuinely interesting. But those trials used oral berberine at doses of 1500mg per day. There is no published evidence that a transdermal patch delivers equivalent amounts.

The supplement industry uses "GLP-1" as marketing shorthand right now because the drugs are culturally dominant. That doesn't mean every product using the term works through the same pathway or produces the same results. Before spending money on a patch, it's worth asking the company for their bioavailability data. If they don't have peer-reviewed absorption studies for their specific transdermal formulation, you're paying for a concept, not a proven delivery system.

For people genuinely exploring options before injectable medications, talking to a clinician about oral berberine, metformin, or regulated telehealth pathways is a more evidence-grounded starting point than a patch with no published pharmacokinetic data.